Genetix Biotherapeutics Analysis: $1.1B Raised
What is Genetix Biotherapeutics?
Transformative genetic therapies for rare diseases
Location
Somerville, United States
Employees
201-500
Founded
1992
Product Features & Capabilities
- LYFGENIA
- ZYNTEGLO
- SKYSONA
- Patient support services
- Clinical trials monitoring
Use Cases
Treat sickle cell disease to alleviate pain crises; Provide beta-thalassemia treatment to reduce transfusion needs; Offer CALD therapy to slow brain damage progression; Support patients with personalized treatment journey assistance; Monitor long-term safety in clinical trial participants
Other Considerations
Transitioned to a privately held company in 2025; Newly appointed leadership team with extensive biotech experience; Strong focus on commercial execution and patient access
See something that needs updating? Suggest edits to this profile.